Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.
Adenocarcinoma
BIOLOGICAL: Ramucirumab (IMC-1121B )|DRUG: Paclitaxel
Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1, DLT based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE v4.02) in Cycle (Cy) 1 due to study drug (SD) with (w/): Grade (Gr) ≥3 neutropenia w/fever ≥38.5°C or w/bacteremia or sepsis, thrombocytopenia w/bleeding and platelet substitution, prothrombin and/or partial thromboplastin time w/no anticoagulation, hyperbilirubinemia; Gr 4: neutropenia \>5 days, thrombocytopenia, Gr 4 or uncontrollable hypertension QTc\>500 milliseconds (ms) or increase ≥100 ms increase in 24 hours after SD or significant arrhythmia in this period; Gr ≥3 nonhematologic toxicity (tox), excluding Gr 3 hypersensitivity, hypertension, injection-site reaction, arthralgia/myalgia, asthenia/fatigue, diarrhea w/out loperamide/nausea/vomiting w/out antiemetic and transient aminotransferase elevation. SD tox=delay \>1 week in ramucirumab (RAM) dose or omission of 1 dose of RAM or 2 paclitaxel doses due to tox in Cy 1 or delay \>2 weeks between Cy 1 and Cy 2 due to persistent tox., Cycle 1 of 28-day cycle|Number of Participants With Adverse Events (AEs), The number of participants who experienced AEs of any grade, AEs of Grade ≥3 or AEs resulting in death that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of serious adverse events (SAEs) and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module., Up to 47 weeks post baseline|Number of Participants With Serious Adverse Events (SAEs), The number of participants who experienced SAEs that were considered to be related to ramucirumab \[RAM (IMC-1121B)\] or paclitaxel (PAC). A summary of SAEs and all other non-SAEs, regardless of causality, is located in the Reported Adverse Events module., Up to 47 weeks post baseline
Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 1, Cmax after a single dose of ramucirumab (IMC-1121B)., Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity), The percentage of participants who were treatment-emergent positive for anti-ramucirumab (IMC-1121B) antibodies., Cycle 1 through Cycle 5 (28-day cycles)|Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 1, AUC from time 0 to infinity (0-∞) after a single dose of ramucirumab (IMC-1121B)., Cycle 1 Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Half-Life (t1/2) for Cycle 1, Terminal t1/2 (the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%) after a single dose of ramucirumab (IMC-1121B)., Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Clearance (CL) or Cycle 1, CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] after a single dose of ramucirumab (IMC-1121B)., Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 1, Vss \[distribution of ramucirumab (IMC-1121B) in the body at steady state\] after a single dose of ramucirumab (IMC-1121B)., Cycle 1: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 2, Cmax after multiple doses of ramucirumab (IMC-1121B)., Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 2, AUC within the dosing interval (0-τ) after multiple doses of ramucirumab (IMC-1121B)., Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Half-Life (t1/2) for Cycle 2, Terminal t1/2 \[the time it takes for the concentration of ramucirumab (IMC-1121B) in plasma or serum to decline by 50%\] after multiple doses of ramucirumab(IMC-1121B)., Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Clearance (CL) for Cycle 2, CL \[the volume of plasma or serum cleared of ramucirumab (IMC-1121B) per unit time\] at steady state after multiple doses of ramucirumab (IMC-1121B)., Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 2, Vss \[distribution of ramucirumab (IMC-1121B) in in the body at steady state\] is not calculated for multiple doses of ramucirumab (IMC-1121B)., Cycle 2: Pre-infusion, Days 1, 2, 3, 5, 8, 12, and 15 of 28-day cycle|Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 3, Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 3., Cycle 3: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 3, Due to the sparse pharmacokinetic sampling ramucirumab (IMC-1121B) AUC within the dosing interval (0-τ) could not be calculated in Cycle 3., Cycle 3: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Half-Life (t 1/2) for Cycle 3, Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) t1/2 could not be calculated in Cycle 3., Cycle 3: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Clearance (CL) for Cycle 3, Due to sparse pharmacokinetic sampling CL could not be calculated for ramucirumab (IMC-1121B) in Cycle 3., Cycle 3: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 3, Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 3., Cycle 3: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Maximum Serum Concentration (Cmax) for Cycle 4, Due to sparse pharmacokinetic sampling ramucirumab (IMC-1121B) Cmax could not be calculated in Cycle 4., Cycle 4: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Area Under the Concentration Time Curve (AUC) for Cycle 4, Due to sparse pharmacokinetic sampling AUC within the dosing interval (0-τ) for ramucirumab (IMC-1121B) could not be calculated in Cycle 4., Cycle 4: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Half-Life (t 1/2) for Cycle 4, Due to sparse pharmacokinetic sampling t1/2 for ramucirumab (IMC-1121B) could not be calculated in Cycle 4., Cycle 4: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Clearance (CL) for Cycle 4, Due to sparse pharmacokinetic sampling CL for ramucirumab (IMC-1121B) could not be calculated in Cycle 4., Cycle 4: Pre-infusion, Day 1 of 28-day cycle|Ramucirumab Steady State Volume of Distribution (Vss) for Cycle 4, Due to sparse pharmacokinetic sampling Vss for ramucirumab (IMC-1121B) could not be calculated in Cycle 4., Cycle 4: Pre-infusion, Day 1 of 28-day cycle
Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.